Vietnam recruits volunteers for trials of ARCT-154 COVID-19 vaccine

by NDO10 August 2021 Last updated at 15:00 PM

The ARCT-154 vaccine will be administered to 100 volunteers at the Hanoi Medical University in Phase I.
The ARCT-154 vaccine will be administered to 100 volunteers at the Hanoi Medical University in Phase I.

VTV.vn - Volunteers are being recruited for clinical trials of ARCT-154, a COVID-19 vaccine developed by a US company, whose manufacturing rights have been secured by VinBioCare, a subsidiary of VinGroup.

Eligible participants must be healthy adults without any underlying conditions, aged between 18-59, with no history of contracting SARS, MERS or COVID-19, and who have not received any other COVID-19 vaccine.

Phase I of the clinical trials is scheduled to begin on August 15, when the ARCT-154 vaccine will be administered to 100 volunteers at the Hanoi Medical University.

Phase II will be conducted on 300 volunteers and Phase III will involve 20,600 volunteers.

In addition to the Hanoi Medical University, the Pasteur Institute in Ho Chi Minh City and the Vietnam Military Medical University will also take part in the clinical trials.

ARCT-154 is a COVID-19 vaccine developed by Arcturus Therapeutics using self-amplifying RNA technology, which has been improved to be effective against the Delta variant.

VinBioCare is planning to build a plant to manufacture this vaccine at the Hoa Lac High-Tech Park on the outskirts of Hanoi.

Tags:

Top VND Exchange Rates

Auto-refesh 15m

USD

EUR

AUD
1 VND
Inverse:
0.00004
22,510.0
0.00004
25,226.0
0.00006
15,674.0

Mid-market rates: 2024-10-09 23:03 UTC

WEATHER FORECAST